Compugen occupies a narrow but defensible niche in cancer immunotherapy that combines computational target discovery with partnered clinical development. The pipeline spans PVRIG, TIGIT, and IL-18 binding protein biology, with two of the assets fully out-licensed to top-tier pharma and two assets in wholly owned development. The economic structure of the franchise resembles a royalty-and-milestone holding company layered on top of a small internal clinical team. The recent AstraZeneca amendment converted a slice of the rilvegostomig royalty stream into $65 million of immediate cash plus an enhanced BLA milestone, materially de-risking the financing timeline. That transaction shifts the dominant equity question from capital access to clinical execution.
The most consequential near-term decision variable is the MAIA-ovarian trial interim analysis, expected in the first quarter of 2027, evaluating COM701 monotherapy as maintenance therapy in relapsed platinum-sensitive ovarian cancer. A positive readout would validate the PVRIG hypothesis in an indication where checkpoint inhibitors have historically underperformed and would likely re-rate the franchise meaningfully. A negative readout would compress the equity toward net cash per share, since the December 2025 inflow and the existing Gilead economics continue to provide a backstop floor. The MAIA-ovarian binary therefore sets the trading range for the equity over the next four to six quarters.
Beneath the headline program, the franchise has a credible late-stage catalyst in rilvegostomig, where AstraZeneca is running multiple late-stage trials. The BLA acceptance milestone is worth $25 million on the near horizon, with longer-dated milestones and a tiered royalty stream providing the structural backstop. GS-0321, in Phase 1, provides a second long-tail partnership option under the Gilead license. Against this pipeline, the franchise reports $73 million of revenue for fiscal 2025. The fiscal 2025 result also includes a $35 million net profit on a one-time royalty monetization. The year-end cash and investments balance is approximately $146 million. The base-case rNPV sits well above the current equity value, with the gap between trading and fundamental value narrowing sharply on any clean PVRIG or TIGIT readout.